Filing Flows › Comparisons › SNOA vs NEPH
Sonoma Pharmaceuticals vs Nephros: SNOA and NEPH compared
Sonoma Pharmaceuticals is the larger company: $6.4M of revenue in its latest quarter (Q1 FY27) against $5.6M for Nephros (Q3 2026). Sonoma Pharmaceuticals is growing faster (+60% against +18% a year earlier). Nephros is more profitable, with an operating margin of 8.9% against -0.6%.
Where the money goes: SNOA and NEPH
Sonoma Pharmaceuticals (SNOA) · Q1 FY27
Sonoma Pharmaceuticals, Q1 FY27: revenue $6.4M (+60% year over year), operating margin -0.6%, net loss $330K, operating cash flow −$649K. The chart follows the revenue to costs, profit and cash.
Nephros (NEPH) · Q3 2026
Nephros, Q3 2026: revenue $5.6M (+18% year over year), operating margin 8.9%, net earnings $512K, operating cash flow −$150K. The chart follows the revenue to costs, profit and cash.
| Sonoma Pharmaceuticals (SNOA) | Nephros (NEPH) | |
|---|---|---|
| Latest quarter | Q1 FY27 | Q3 2026 |
| Revenue | $6.4M | $5.6M |
| Revenue growth, Y/Y | +60% | +18% |
| Gross margin | — | 58.4% |
| Operating margin | -0.6% | 8.9% |
| Net earnings | −$330K | $512K |
| Net margin | -5.2% | 9.1% |
| Operating cash flow | −$649K | −$150K |
Where the revenue comes from
Nephros
- Product: $5.4M (97%)
- Service Royalty and Other Revenues: $191K (3%)
Questions
Which is bigger, Sonoma Pharmaceuticals or Nephros?
Sonoma Pharmaceuticals is the larger company: $6.4M of revenue in its latest quarter (Q1 FY27) against $5.6M for Nephros (Q3 2026).
Is Sonoma Pharmaceuticals or Nephros growing faster?
Sonoma Pharmaceuticals is growing faster (+60% against +18% a year earlier).
Which is more profitable, Sonoma Pharmaceuticals or Nephros?
Nephros is more profitable, with an operating margin of 8.9% against -0.6%.
More: Sonoma Pharmaceuticals earnings · how Sonoma Pharmaceuticals makes money · Nephros earnings · how Nephros makes money
From the companies' latest 10-Q, 10-K or earnings release (10-Q filed Aug 6, 2026; 10-Q filed Nov 5, 2026). Fiscal quarters can end on different dates. Not investment advice.